Skip to main content
Premium Trial:

Request an Annual Quote

Shimadzu to Collaborate with Phenomenome in Biomarker Discovery, Proteomic Studies

NEW YORK, June 19 (GenomeWeb News) - Shimadzu and Phenomenome Discoveries have agreed to collaborate exclusively to develop tools for biomarker discovery and global profiling studies, including proteomic studies, the companies said today.

 

A year ago, Shimadzu and Phenomenome inked a deal that allowed researchers to use Phenomenome's informatics platform to visualize and interpret mass spectrometry data generated by Shimadzu technology for metabolomics research.

 

The current agreement extends this previous agreement by further integrating mass spectrometry data generated on Shimadzu's LCMS-IT-TOF systems with Phenomenome's Profiler informatics platform, Shimadzu said.

 

"The collaboration with Phenomenome has been enhanced to take into account the growing need of researchers working in biomarker discovery and comparative proteomics studies to use high mass accuracy MSn data," said Kozo Shimazu, Shimadzu's deputy general manager in the analytical and measuring instrument division. "We believe that this collaboration ... helps deliver a unique and integrated solution to help find components of biological significance."

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.